The Food and Drug Administration has approved an effective combination treatment for patients with advanced prostate cancer. Prostate cancer is the second leading cause of cancer death in men and// according to the American Cancer Society, there will be about 230,900 new cases of prostate cancer diagnosed this year.

The combination therapy consists of Taxotere (docetaxel) and prednisone (a steroid). Researchers say the treatment has shown promise for many patients.Researchers say it is an important advance in the treatment of prostate cancer because it can help some patients live longer. Specialists say Taxotere in combination with prednisone offers hope to certain patients who have not responded to other treatments.

Taxotere works by stopping tubulin -- a protein that helps cancer cells divide and grow. The drug Taxotere in combination with prednisone was found to extend the lifespan of patients by about 2.5 months.Side effects of the drug combination include nausea, hair loss, bone marrow suppression, tingling sensations, and fluid retention.
'"/>




Page: 1
Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients